This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jun 22;381(9884):2141-3.

doi: 10.1016/S0140-6736(13)60065-3. Epub 2013 Apr 4.

Anti-interleukin-2 receptor alpha for multiple sclerosis?

Shiv Saidha¹, Peter A Calabresi

Affiliations

PMID: 23562008
DOI: 10.1016/S0140-6736(13)60065-3

Comment

Anti-interleukin-2 receptor alpha for multiple sclerosis?

Shiv Saidha et al. Lancet. 2013.

. 2013 Jun 22;381(9884):2141-3.

doi: 10.1016/S0140-6736(13)60065-3. Epub 2013 Apr 4.

Authors

Shiv Saidha¹, Peter A Calabresi

Affiliation

¹ Department of Neurology, Beaumont University Hospital, Dublin, Ireland.

PMID: 23562008
DOI: 10.1016/S0140-6736(13)60065-3

No abstract available

PubMed Disclaimer

Comment on

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators. Gold R, et al. Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4. Lancet. 2013. PMID: 23562009 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations